Nancy Andrews, DO
Endocrinology, Diabetes & Metabolism · Sterling Heights, MINPI 1427077916
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 1,316 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 57 manufacturers, the largest accounting for just 12.0% — the pattern of someone who eats at a lot of different presentations.
Across 1,316 payments — averaging $15.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Medtronic$2K
- Amgen$1K
- Lilly USA, LLC$1K
- Sanofi-aventis U.S. LLC$1K
- AstraZeneca$1K
- plus $11K from 51 others
What the payments were for
- Speaking & faculty fees$3001%
- Food & beverage$19,86598%
- Education$1081%
- Gifts$770%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JUXTAPID$300
- Minimed 770G System$166
- INTELLIS ADAPTIVESTIM$157
- MINIMED 780G$155
- InPen$138
- Minimed 670G System$114
- MINIMED 770G$113
How this compares
$20,350 in reported general payments places this provider in the 85th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
See all endocrinology, diabetes & metabolism providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 242 | $509,511 |
| TrulicityDulaglutide | 235 | $486,497 |
| JardianceEmpagliflozin | 293 | $406,657 |
| FarxigaDapagliflozin Propanediol | 129 | $167,461 |
| JanuviaSitagliptin Phosphate | 118 | $146,270 |
| MounjaroTirzepatide | 84 | $146,164 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 69 | $126,566 |
| Tresiba Flextouch U-100Insulin Degludec | 124 | $112,136 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 122 | $97,229 |
| Novolog FlexpenInsulin Aspart | 192 | $79,531 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 382 | $70,822 |
| Humalog Kwikpen U-100Insulin Lispro | 148 | $68,382 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 44 | $62,241 |
| Bydureon BciseExenatide Microspheres | 27 | $61,717 |
| Tresiba Flextouch U-200Insulin Degludec | 24 | $51,131 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $1,342 | $658,464382 claims |
| Novo NordiskOzempic, Novolog | $2,436 | $539,529338 claims |
| Boehringer IngelheimJardiance, Tradjenta | $739 | $429,202311 claims |
| AstraZenecaFarxiga | $1,046 | $167,461129 claims |
| MerckJanuvia | $417 | $146,270118 claims |
| Johnson & JohnsonInvokana | $155 | $50,69737 claims |
| Alvogen IncTeriparatide | $119 | $40,21611 claims |
| AbbVieSynthroid | $1,038 | $30,995252 claims |
| AmgenProlia | $1,420 | $18,50211 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $679 | $15,2151,196 claims |
| Sanofi-aventis U.S. LLCLantus | $1,313 | $8,23242 claims |
| IBSA Pharma Inc.Tirosint | $132 | $6,29622 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
Other endocrinology, diabetes & metabolism in Sterling Heights
- Eric LangerSterling Heights$213K
- Amy TobinSterling Heights$37K
- Lowell SchmeltzFarmington Hills$1.3M
- George GrunbergerBloomfield Hills$931K
- Gary EdelsonFarmington Hills$503K
- Michael BrennanSaint Clair Shores$433K
- Jamal HammoudFlint$386K
- Abdulsalam Al KassabRochester Hills$351K
- Richard AuchusAnn Arbor$250K
- Ashish VermaShelby Twp$179K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.